Pfizer (PFE) Revenue (2009 - 2026)

Pfizer (PFE) has 18 years of Revenue data on file, last reported at $2.3 billion in Q1 2026.

• Revenue for Q1 2026 came in at $2.3 billion, up 10.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.5 billion (down 20.35% YoY), and the FY2025 annual result was $62.6 billion, up 646.05% from the prior year.
• Revenue retreated to $2.3 billion in Q1 2026 per PFE's latest filing, from $17.6 billion in the prior quarter.
• Over five years, Revenue peaked at $27.7 billion in Q3 2022 and troughed at $442.0 million in Q3 2024.
• A 5-year average of $9.2 billion and a median of $3.5 billion in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2025: Revenue plunged 92.73% in 2023, then surged 419.91% in 2025.
• A 5-year view of Revenue shows it stood at $3.3 billion in 2022, then advanced by 5.31% to $3.4 billion in 2023, then tumbled by 87.13% to $442.0 million in 2024, then jumped by 3872.17% to $17.6 billion in 2025, then tumbled by 86.68% to $2.3 billion in 2026.
• Business Quant data shows PFE's Revenue at $2.3 billion in Q1 2026, $17.6 billion in Q4 2025, and $2.3 billion in Q3 2025.